



March 25, 2022

2022-SMT-0041
10 CFR 50.30

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
Washington, DC 20555

- References:
- (1) SHINE Medical Technologies, LLC letter to the NRC, "SHINE Medical Technologies, LLC Application for an Operating License," dated July 17, 2019 (ML19211C143)
 - (2) NRC letter to SHINE Technologies, LLC, "SHINE Medical Technologies, LLC – Request for Confirmatory Information Related to the Electrical Power Systems (EPID No. L-2019-NEW-0004)," dated March 21, 2022 (ML22075A336)

SHINE Technologies, LLC Application for an Operating License
Response to Request for Confirmatory Information

Pursuant to 10 CFR Part 50.30, SHINE Technologies, LLC (SHINE) submitted an application for an operating license for a medical isotope production facility to be located in Janesville, Wisconsin (Reference 1). The NRC staff determined that confirmatory information was required to enable the staff's continued review of the SHINE operating license application (Reference 2).

Enclosure 1 provides the SHINE responses to the NRC staff's request for confirmatory information.

If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.

I declare under the penalty of perjury that the foregoing is true and correct.
Executed on March 25, 2022.

Very truly yours,

DocuSigned by:

F52DB96989224FF...

James Costedio
Vice President of Regulatory Affairs and Quality
SHINE Technologies, LLC
Docket No. 50-608

Enclosure

cc: Project Manager, USNRC
SHINE General Counsel
Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health

ENCLOSURE 1

SHINE TECHNOLOGIES, LLC

SHINE TECHNOLOGIES, LLC APPLICATION FOR AN OPERATING LICENSE RESPONSE TO REQUEST FOR CONFIRMATORY INFORMATION

The U.S. Nuclear Regulatory Commission (NRC) staff determined that confirmatory information was required (Reference 1) to enable the continued review of the SHINE Technologies, LLC (SHINE) operating license application (Reference 2). The following information is provided by SHINE in response to the NRC staff's request.

Chapter 8 – Electrical Power Systems

RCI 8-11

FSAR Section 8a2.2, "Emergency Electrical Power Systems," states, in part, "The UPSS [uninterruptible electric power supply system] consists of a 125-volt direct current (VDC) battery subsystem, inverters, bypass transformers, distribution panels, and other distribution equipment necessary to feed safety-related alternating current (AC) and direct current (DC) loads and select nonsafety-related AC and DC loads." FSAR Section 8a2.2.1, "Uninterruptible Electrical Power Supply System Design Basis," states, in part, that the UPSS "is designed, fabricated, erected, tested, operated, and maintained to quality standards commensurate with the importance of the safety functions to be performed." The onsite safety functions are to provide sufficient capacity and capability per Criterion 27.

The NRC staff finds that that the licensee does not provide a description in the FSAR of the safety classification of UPSS subcomponents, (e.g., cables, connectors, etc.).

Confirm that the UPSS subcomponents used to support safety-related loads in FSAR Table 8a2.2-1, "UPSS Load List," are designated as safety-related. If the UPSS subcomponents are not safety-related, provide an explanation of how the subcomponents meets Criterion 27 for capability and demonstrate how the subcomponent will perform its safety function, (i.e., identify relevant standards).

SHINE Response

SHINE confirms that the uninterruptible power supply system (UPSS) subcomponents (e.g., cables, connectors) used to support safety-related loads in Table 8a2.2-1 of the FSAR are designated as safety-related.

References

1. NRC letter to SHINE Technologies, LLC, "SHINE Medical Technologies, LLC – Request for Confirmatory Information Related to the Electrical Power Systems (EPID No. L-2019-NEW-0004)," dated March 21, 2022 (ML22075A336)
2. SHINE Medical Technologies, LLC letter to the NRC, "SHINE Medical Technologies, LLC Application for an Operating License," dated July 17, 2019 (ML19211C143)